23 October 2026
Biogaran v. Lundbeck and the Challenger’s Burden in Second Medical Use Cases
11 October 2026
An opt-out is not a register entry: ownership and procedural choice before the UPC
10 October 2026
Pleading the long arm: what a UPC statement of claim must carry
9 October 2026
Entering the European market: the four questions that decide the timetable
8 October 2026
Munich’s FRAND guidelines: the illusion of precision
3 October 2026
Pharmaceutical patents and the UPC: is the Court hostile to them?
2 October 2026
Brexit and the UPC: where British patent holders now stand
25 September 2026
Unitary and National Patents: A Quest for Coherence
23 September 2026
The Transitional Period and the UPC: Coordinating Two Judicial Orders
22 September 2026
Preliminary References and the UPC: the Question of Jurisdiction
21 September 2026
Appeals before the UPC: what the figures show
20 September 2026
FRAND devant la JUB : les solutions retenues et les questions ouvertes
19 September 2026
SMEs and the UPC: Cost as a Barrier to Access to Justice
18 September 2026
Procedural Uncertainty and the UPC: Provisional Measures, Evidence and Costs
17 September 2026
The World Without the UPC: How a Successful Court Could Still Disappear
16 September 2026
G 1/25: the description as a tool for interpreting the claims
14 September 2026
Valeo v. Bosch: the allocation of cases within the UPC, an alternative and not an exception
11 September 2026
La saisie-contrefaçon, l’arme française que les titulaires étrangers oublient
10 September 2026
The launch letter before the UPC: preventing urgency for generics and biosimilars
5 September 2026
Portfolio strategy and the UPC: where the value of life sciences assets lies
5 September 2026
Merz v. Viatris on appeal: urgency remains decisive, but not every signal is urgent
4 September 2026
UPC and life sciences: the first strategic lessons
4 September 2026
The UPC's long-arm jurisdiction: how far the arm reaches, where the effect stops
3 September 2026
Imminent infringement before the UPC: the new geography of pharmaceutical risk
3 September 2026
The PMAC Rules: patent arbitration through the FRAND lens
2 September 2026
The UPC did not end parallel litigation: it turned it into a weapon
1 September 2026
Damages before the UPC: from compensation to a market reference
31 August 2026
Forum shopping before the UPC: the map, the language and Article 33
30 August 2026
Anti-anti-suit injunctions before the UPC: Europe strikes back
30 August 2026
UPC evidence preservation orders: the UPC saisie in practice
24 February 2025
The UPC's first FRAND decision: Panasonic v Oppo, and what came next
30 July 2024
Sanofi v Amgen: the UPC’s first revocation action and the patentability of therapeutic antibodies, from revocation to reversal
29 July 2024
Comparable licenses before the UPC: compelled production and confidentiality clubs
29 July 2024
Panasonic cases: Clarification on the production of comparable licenses before UPC (orders to produce evidence)
29 July 2024
UPC’s Order to Produce Evidence: Huawei vs. Netgear
24 July 2024
Sanofi vs. Amgen: Successful first UPC revocation action and strict assessment of therapeutic antibodies patentability
22 July 2024
The UPC’s first ruling on an infringement action by the Paris local division
6 May 2024
UPC and Proportionality: Will the EU enters through the back door? (From 10xGenomics case to UPC “seizure”)
30 April 2024
Release of a treaty on patent law co-authored by Matthieu Dhenne
4 April 2024
UPC “seizure” Part IV: the appeal against the “seizure” order
22 March 2024
UPC “seizure” Part III: the “C-Kore” case
18 March 2024
UPC seizure Part II: the “OERLIKON” case
14 March 2024
UPC seizure Part I: the texts
5 June 2023
UPC: brief thoughts from a French “UPC Representative”
23 April 2023
Conflicts between UPCA and national laws: a dangerous riddle?
1 March 2023
Some light for the sunrise: 5 questions for 5 French UPC judges